SEPTInvestingStart Free

KROS 10-Q: SEC filing

Keros Therapeutics

Filed with the SEC on · accession 0001664710-26-000066

KROS filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. Keros Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, accompanied by the standard CEO certification under Sarbanes-Oxley Section 302. The stock moved -12.7% by the first close after the filing.

Summary of the filing

Keros Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, accompanied by the standard CEO certification under Sarbanes-Oxley Section 302. The certification confirms the accuracy of the financial statements and the effectiveness of disclosure controls and procedures.

For details, click here →How to read a 10-Q →

Key details

RegistrantKeros Therapeutics, Inc.
Chief executive officer (principal executive officer)Jasbir Seehra, Ph.D.

How KROS stock reacted

Close before

$10.83

Nov 4, 2026

First close after

-12.74%

$9.45

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for KROS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for KROS?

Click here

Frequently asked questions

What did KROS file with the SEC on Nov 5, 2026?

KROS filed a 10-Q (SEC filing). Keros Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, accompanied by the standard CEO certification under Sarbanes-Oxley Section 302. The certification confirms the accuracy of the financial statements and the effectiveness of disclosure controls and procedures.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did KROS stock react to this filing?

KROS closed at $10.83 before the filing and $9.45 on Nov 5, 2026 (-12.74%).

Other KROS SEC filings

Get alerts when KROS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
KROS overviewKROS analysisKROS newsLatest SEC filings